European Indapamide Market to Reach $48.3 Million by 2035

European indapamide market was valued at $36.3 million in 2025 and is projected to reach $48.3 million by 2035, growing at a CAGR of 2.9% during the forecast period (2026–2035). The increasing burden of hypertension and cardiovascular diseases across Europe is significantly driving demand for thiazide-like diuretics such as indapamide. As healthcare systems emphasize cost-effective long-term management of chronic conditions, indapamide continues to gain traction due to its proven efficacy in blood pressure control and favourable safety profile. The growing aging population and rising prevalence of lifestyle-related disorders are further strengthening prescription volumes across both primary and secondary care settings.

Browse the full report description of “European Indapamide Market Size, Share & Trends Analysis Report, By Product Type (Immediate-Release (IR) Tablets, and Sustained/Extended-Release (SR/ER) Tablets), By Strength (1.25 mg, 2.5 mg, and Other Customized Dosages), and By Application (Hypertension, Edema (Fluid Retention), Heart Failure (Adjunct Therapy)), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/european-indapamide-market

Hypertension remains the leading application segment, while edema and adjunct therapy in heart failure support consistent demand across hospital and outpatient care. The market is witnessing sustained adoption of sustained/extended-release (SR/ER) formulations, which improve patient adherence and therapeutic outcomes. Pharmaceutical companies are increasingly focusing on optimized dosage strengths and formulation innovations to align with evolving clinical guidelines and patient compliance requirements.

Rising Hypertension Burden and Public Health Initiatives in Europe

In Europe, hypertension continues to be a major public health concern, directly influencing the demand for antihypertensive therapies such as indapamide. Additionally, data from the European Commission indicates that cardiovascular diseases account for nearly 1.8 million deaths annually across the European Union, reinforcing the urgency for effective blood pressure management strategies.

To address this growing burden, governments and healthcare bodies are actively implementing national screening and treatment programs. For instance, in 2024, multiple EU member states expanded primary care-based hypertension screening initiatives under broader non-communicable disease (NCD) strategies, improving early diagnosis and treatment uptake. These developments are directly supporting the demand for established, guideline-recommended medications such as indapamide, particularly in first-line and combination therapy settings.

Regulatory Support and Industry Strategies Driving Market Expansion

The European pharmaceutical landscape is witnessing increased alignment with evidence-based treatment protocols and affordability initiatives, further supporting indapamide adoption. In 2023, the European Medicines Agency reinforced the importance of standardized antihypertensive therapies through updated clinical recommendations and ongoing pharmacovigilance programs, ensuring the continued safety and efficacy of widely used diuretics. The leading pharmaceutical companies are actively strengthening their market presence through portfolio expansion, generic penetration, and combination drug offerings.

The key players in the European indapamide market include Servier (Natrilix / Lozol), Teva Pharmaceuticals, Sanofi, Viatris, and Sandoz, among others. These companies are focusing on strengthening their generic drug portfolios and improving access to cost-effective therapies across Europe.

• In April 2024, Zentiva

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
  • By Product Type
  • By Strength
  • By Application
• Competitive Landscape – Servier, Teva Pharmaceuticals, Sanofi, Viatris, and Sandoz, among others.

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• Who are the leading players in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

European Indapamide Market Segment

By Product Type

• Immediate-Release (IR) Tablets
• Sustained/Extended-Release (SR/ER) Tablets

By Strength

• 25 mg
• 5 mg
• Other Customized Dosages

By Application

• Hypertension
• Edema (Fluid Retention)
• Heart Failure (Adjunct Therapy)

European Indapamide Market Segment by Country

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-indapamide-market